CN105188380B - Lxr调节剂 - Google Patents

Lxr调节剂 Download PDF

Info

Publication number
CN105188380B
CN105188380B CN201480027521.4A CN201480027521A CN105188380B CN 105188380 B CN105188380 B CN 105188380B CN 201480027521 A CN201480027521 A CN 201480027521A CN 105188380 B CN105188380 B CN 105188380B
Authority
CN
China
Prior art keywords
methyl
alkyl
methylsulfonyl
biphenyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480027521.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105188380A (zh
Inventor
E.K.基克
M.博达斯
R.莫汉
B.B.布施
C.阿弗布
M.瓦伦特
N.乌尔茨
P.S.M.劳
J.谢蒂
A.维努
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Bristol Myers Squibb Co
Exelixis Patent Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Exelixis Patent Co LLC filed Critical Bristol Myers Squibb Co
Publication of CN105188380A publication Critical patent/CN105188380A/zh
Application granted granted Critical
Publication of CN105188380B publication Critical patent/CN105188380B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201480027521.4A 2013-03-15 2014-03-14 Lxr调节剂 Expired - Fee Related CN105188380B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787422P 2013-03-15 2013-03-15
US61/787422 2013-03-15
PCT/US2014/027679 WO2014152738A1 (en) 2013-03-15 2014-03-14 Lxr modulators

Publications (2)

Publication Number Publication Date
CN105188380A CN105188380A (zh) 2015-12-23
CN105188380B true CN105188380B (zh) 2017-08-15

Family

ID=51581300

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480027521.4A Expired - Fee Related CN105188380B (zh) 2013-03-15 2014-03-14 Lxr调节剂

Country Status (6)

Country Link
US (1) US9751869B2 (enExample)
EP (1) EP2967073B9 (enExample)
JP (1) JP6456909B2 (enExample)
CN (1) CN105188380B (enExample)
ES (1) ES2694001T3 (enExample)
WO (1) WO2014152738A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144037A1 (en) 2013-03-15 2014-09-18 Bristol-Myers Squibb Company Lxr modulators
ITUA20164199A1 (it) * 2016-06-08 2017-12-08 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Modulatori di soce compisizioni e relativi usi
WO2018091389A1 (en) 2016-11-17 2018-05-24 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulphur containing substituents
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN113457708B (zh) * 2021-06-30 2023-10-20 常州大学 CoN@C多孔材料及其制备方法以及在芳香族腈类化合物的合成中的应用
EP4536655A2 (en) * 2022-06-10 2025-04-16 Sionna Therapeutics Inc. Compounds, compositions, and methods of using thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908852A (en) * 1994-11-14 1999-06-01 G. D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0252290B1 (en) 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
WO2000078972A2 (en) 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Regulation with binding cassette transporter protein abc1
WO2001082917A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US7247735B2 (en) * 2002-07-26 2007-07-24 Infineon Technologies Ag Octupolar molecules used as organic semiconductors
AU2003293376A1 (en) 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
CA2522476A1 (en) 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
JP2008533200A (ja) * 2005-03-21 2008-08-21 メルク エンド カムパニー インコーポレーテッド 置換アリールおよびヘテロアリール誘導体、かかる化合物を含有する組成物および使用法
MX2008000141A (es) 2005-06-27 2008-04-07 Exelixis Inc Moduladores de lxr basados en imidazol.
EP2121621B1 (en) * 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
DK2435410T3 (da) 2009-05-28 2017-04-10 Exelixis Patent Co Llc LXR-modulatorer
HUE040231T2 (hu) * 2012-03-02 2019-02-28 Ralexar Therapeutics Inc Máj X receptor (LXR) modulátorok bõrbetegségek, rendellenességek és állapotok kezelésére
WO2014144037A1 (en) 2013-03-15 2014-09-18 Bristol-Myers Squibb Company Lxr modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908852A (en) * 1994-11-14 1999-06-01 G. D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation

Also Published As

Publication number Publication date
ES2694001T3 (es) 2018-12-17
JP2016518334A (ja) 2016-06-23
US9751869B2 (en) 2017-09-05
WO2014152738A1 (en) 2014-09-25
ES2694001T9 (es) 2019-07-12
EP2967073A4 (en) 2016-10-12
CN105188380A (zh) 2015-12-23
EP2967073A1 (en) 2016-01-20
EP2967073B9 (en) 2019-04-10
US20160289222A1 (en) 2016-10-06
JP6456909B2 (ja) 2019-01-23
EP2967073B1 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
CN105209039B (zh) Lxr调节剂
TWI714527B (zh) 醯胺類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用
CN105188380B (zh) Lxr调节剂
CN101679297B (zh) Lxr和fxr调节剂
JP5934670B2 (ja) ジアリールチオヒダントイン化合物
CN103189361B (zh) 雌激素受体调节剂及其用途
JP7593647B2 (ja) ヒストン脱アセチル化酵素阻害剤としての１，３，４－オキサジアゾール誘導体
JP2013503129A (ja) テトラ−置換ヘテロアリール化合物ならびにｍｄｍ２および／またはｍｄｍ４モジュレーターとしてのそれらの使用
JP2001508799A (ja) 新規カンナビノイド受容体モジュレータ
WO2003103654A1 (ja) ＮＦ−κＢ活性化阻害剤
WO2003103657A1 (ja) 神経変性疾患治療剤
CZ243093A3 (en) Benzofuran derivatives, process of their preparation and pharmaceutical preparations in which they are comprised
CN103517896A (zh) 喹啉酮衍生物
CN108929281B (zh) 三氮唑类化合物及其合成方法和应用
JP2022516969A (ja) 金属酵素阻害剤化合物
JP6821737B2 (ja) 肝臓ｘ受容体（ｌｘｒ）のモジュレーター
RU2407736C2 (ru) Пери-замещенные арилсульфонамидные бициклические соединения, предназначенные для лечения окклюзионного заболевания артерий
WO2004031180A1 (ja) キナゾリン−４−オン誘導体
EP4650002A1 (en) Aniline-based modulators of the nuclear receptor tlx (nr2e1)
CN101821236A (zh) 五元杂环化合物
JP2009510042A (ja) Ｐｐａｒ作動薬ｉｉとしての縮合ピラゾール誘導体
KR20050073110A (ko) 간 ｘ 수용체의 항진제

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20190329

Address after: California, USA

Patentee after: EXELIXIS PATENT Co.,LLC

Address before: New jersey, USA

Co-patentee before: EXELIXIS PATENT Co.,LLC

Patentee before: BRISTOL-MYERS SQUIBB Co.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210521

Address after: California, USA

Patentee after: EXELIXIS, Inc.

Address before: California, USA

Patentee before: EXELIXIS PATENT Co.,LLC

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170815

CF01 Termination of patent right due to non-payment of annual fee